Why Provenya’s Capabilities Are Relevant
Healthcare is classified as a high-risk domain under the EU AI Act, meaning AI systems used in diagnosis, treatment, patient management, and clinical decision support face the most stringent compliance requirements in European law. With the high-risk obligations coming into force from August 2026, healthcare organisations and their technology providers face an urgent need to build governance infrastructure that satisfies regulators, procurement bodies, and clinical governance boards simultaneously.
The European Health Data Space (EHDS), expected to reach operational maturity by 2026, will further transform how health data is shared across borders—creating new opportunities for AI-driven diagnostics and personalised medicine, but also demanding robust data governance, provenance tracking, and rights management at scale.
Provenya’s capabilities address this landscape directly: our training builds AI literacy across clinical, R&D, IT, and governance teams; our compliance services produce the documentation and evidence packs that the EU AI Act demands; our provenance lab creates traceable data pipelines for validation and auditability; and our IP services ensure that health AI products are structured for licensing and procurement.
Enhancing Commercial Value
- Procurement readiness: Hospital and health authority procurement increasingly requires suppliers to demonstrate EU AI Act compliance, DPIA completion, and audit-grade documentation. Provenya’s evidence packs meet these requirements directly, reducing sales cycles and increasing win rates
- Faster regulatory pathways: Medical device and software-as-medical-device (SaMD) manufacturers benefit from compliance-by-design documentation that aligns with both the EU AI Act and MDR requirements, eliminating the costly retroactive remediation that delays market entry
- Cross-border scalability: The EHDS creates a single market for health data services. Organisations with robust provenance and governance infrastructure will be first movers in this market
- Investor confidence: Health AI startups and scale-ups with documented compliance infrastructure command higher valuations and stronger due diligence outcomes
Go-to-Market Strategy
Provenya’s go-to-market in healthcare follows a three-tier approach:
- Tier 1 — EU Project Entry: Position as the governance, compliance, and provenance partner in Horizon Europe health clusters. The 2026–2027 work programme allocates significant funding to health AI with explicit requirements for trustworthy AI and data governance
- Tier 2 — SME Enablement: Offer compliance readiness packages to health AI SMEs preparing for high-risk obligations. These SMEs need procurement-ready evidence packs but lack internal governance capability
- Tier 3 — Health System Partnerships: Engage hospitals and health authorities through brokerage services, connecting them with validated technology providers and facilitating pilot deployments with built-in governance
Strengthening EU Innovation at the Global Stage
The EU’s approach to health AI regulation is being watched globally. Countries including Canada, Australia, Singapore, and the UK are developing frameworks that draw on the EU AI Act’s risk-based approach. Organisations that achieve EU compliance first will have a competitive advantage in these emerging markets.
Provenya’s contribution strengthens Europe’s position by ensuring that EU-developed health AI products are not only compliant but also commercially deployable across jurisdictions—with governance infrastructure that translates into global trust and market access.
Commercial Impact Summary: The healthcare AI market in Europe requires compliance infrastructure as a precondition for market entry. Provenya transforms this requirement from a barrier into a competitive advantage—enabling health AI providers to reach procurement, pass regulatory review, and scale across the European Health Data Space with confidence.